Clinical Trial Update: A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 study evaluating dabrafenib (GSK2118436) in patients with BRAF-mutant metastatic melanoma with brain metastases;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Melanoma and Brain Metastases | Phase 2 | Status: COMPLETED | Results posted: 2014-03-05